Review of Research Paper on Parkinson's Disease Treatment

Abstract Attempts to cure or delay the progression of Parkinson's disease have largely failed; researchers believe that this is clearly a direct result of the lack of insight into the pathogenesis of the disease. Parkinson's disease is the product of many dopaminergic (dopamine secreting) neuronal deaths in the substantia nigra pars compacta (SNc). However, Chen and researchers found that these death causes' 'rejuvenation' protects neurons in mouse models of Parkinson's disease '' that senile neurons of SNc are abnormally dependent on calcium channels did. And start actin

Dr. Bu is one of the world's leading researchers specializing in the possibility of cell therapy for Parkinson's disease. Parkinson's disease is a rather direct disease because its cause is well-known: cell death producing chemical dopamine. Still, there are many challenges to developing therapy. The design of the clinical trial (including, for example, careful selection of patients with Parkinson's disease.Bark points out that there are mainly two types of progression of Parkinson's disease, one may respond to treatment, The other may not be in the back). "The lack of severity of patients over the past 25 years has plagued this area," he commented. Preclinical studies need to deal with several other factors as well. For example, determine the optimal cell type to use, how to extend them, make them GMP compliant, standardize for reproducibility, etc.

Shelly: My paper project focuses on the development of new treatments for the treatment of neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Parkinson's disease. All of these diseases have one thing in common. Brain cells gradually accumulate toxic proteins and inhibit the normal molecular mechanism of the cells. As these proteins accumulate, neurons die. There is some evidence that removing toxic proteins contributes to neuronal survival and delay of symptoms (at least in mice). I led the project to develop a modular peptide drug for protein knockout. Once injected into the bloodstream, it passes through the blood brain barrier, grabs its target toxic protein, and drags it into cellular organelle called lysosome, the cell's own waste treatment system. Peptides can be customized for different kinds of toxic proteins by exchanging one of the modules (eg Lego).